Allergic rhinitis symptom prevalence (proxy for allergy ‘outburst’ susceptibility) by country
Country share of adults reporting allergic rhinitis (hay fever) symptoms—used as a proxy for population susceptible to seasonal allergy outbursts (2022).
Loading visualization...
Key Insights
- •Reported adult allergic rhinitis symptom prevalence spans roughly 6%–30% across included countries (2022 proxy).
- •Higher prevalence is observed in several high-income countries (e.g., USA, Australia, Netherlands, Canada, Sweden, UK).
- •Lower reported prevalence appears in parts of South/Southeast Asia (e.g., Vietnam, Bangladesh, Indonesia), though underdiagnosis/underreporting may contribute.
- •European countries cluster in the mid-to-high range, consistent with substantial seasonal allergy susceptibility.
Country Rankings
Top 10 Countries
Bottom 10 Countries
Data Analysis
Value Distribution
How countries are distributed across the value range
Regional Comparison
Average values by world region (Global avg: 16.7%)
About This Statistic
There is no globally standardized indicator for “outburst population” (people experiencing acute spikes) that is consistently reported by country across all regions. To enable a world map, this statistic uses the most comparable country-level proxy available: the prevalence of allergic rhinitis (hay fever/nasal allergy) symptoms among adults from international allergy survey reporting.
This proxy reflects the share of the population likely to experience seasonal symptom flare-ups during high-allergen periods (often pollen-driven), and it is commonly used to compare allergy burden between countries. It does not measure a specific short-term outburst event, but it approximates the underlying susceptible population that can drive visible “outbursts” when pollen/allergen conditions spike.
Methodology
Values represent the estimated percentage of adult respondents reporting allergic rhinitis (hay fever/nasal allergy) symptoms in internationally reported survey comparisons summarized by WAO. For the map, each country is assigned the reported prevalence percentage. This is used as a proxy for the ‘outburst population’—i.e., the share of people likely to experience symptom flare-ups when allergen conditions (often pollen) spike.
Full Data
| Rank ↑ | Country ↕ | Value ↕ |
|---|---|---|
| 1 | United States of America | 30.0% |
| 2 | Australia | 29.0% |
| 3 | Canada | 28.0% |
| 4 | Netherlands | 28.0% |
| 5 | New Zealand | 27.0% |
| 6 | Sweden | 27.0% |
| 7 | Denmark | 26.0% |
| 8 | United Kingdom | 26.0% |
| 9 | Ireland | 25.0% |
| 10 | Japan | 25.0% |
| 11 | Norway | 25.0% |
| 12 | France | 24.0% |
| 13 | Switzerland | 24.0% |
| 14 | Belgium | 24.0% |
| 15 | Germany | 23.0% |
| 16 | Austria | 22.0% |
| 17 | Spain | 21.0% |
| 18 | Italy | 20.0% |
| 19 | South Korea | 20.0% |
| 20 | Czech Republic | 19.0% |
| 21 | Portugal | 19.0% |
| 22 | Poland | 18.0% |
| 23 | Brazil | 18.0% |
| 24 | Chile | 17.0% |
| 25 | Greece | 17.0% |
| 26 | Hungary | 16.0% |
| 27 | Türkiye | 16.0% |
| 28 | The Republic of North Macedonia | 16.0% |
| 29 | Colombia | 15.0% |
| 30 | Croatia | 15.0% |
| 31 | Mexico | 14.0% |
| 32 | Romania | 14.0% |
| 33 | Bangladesh | 14.0% |
| 34 | Bulgaria | 13.0% |
| 35 | Guatemala | 13.0% |
| 36 | South Africa | 13.0% |
| 37 | Argentina | 13.0% |
| 38 | Georgia | 12.0% |
| 39 | Honduras | 12.0% |
| 40 | Lebanon | 12.0% |
| 41 | Peru | 12.0% |
| 42 | Serbia | 12.0% |
| 43 | Singapore | 12.0% |
| 44 | United Arab Emirates | 12.0% |
| 45 | Saudi Arabia | 11.0% |
| 46 | Ukraine | 11.0% |
| 47 | Islamic Republic of Iran | 10.0% |
| 48 | Russian Federation | 10.0% |
| 49 | People's Republic of China | 9.0% |
| 50 | Morocco | 9.0% |
| 51 | Thailand | 9.0% |
| 52 | India | 8.0% |
| 53 | Philippines | 8.0% |
| 54 | Indonesia | 7.0% |
| 55 | Pakistan | 7.0% |
| 56 | Paraguay | 7.0% |
| 57 | Vietnam | 6.0% |
Topics
Data Source
This data comes from World Allergy Organization (WAO) – White Book on Allergy (country-comparable survey reporting) (2022).
View Original Source